Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

907 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer.
Nishimura K, Nishio K, Hirosuna K, Komura K, Hayashi T, Fukuokaya W, Ura A, Uchimoto T, Nakamura K, Fukushima T, Yano Y, Takahashi N, Nakamori K, Kinoshita S, Matsunaga T, Tsutsumi T, Tsujino T, Taniguchi K, Tanaka T, Uehara H, Takahara K, Inamoto T, Hirose Y, Kimura T, Egawa S, Azuma H. Nishimura K, et al. Among authors: uehara h. J Immunother Cancer. 2022 Jan;10(1):e003868. doi: 10.1136/jitc-2021-003868. J Immunother Cancer. 2022. PMID: 35039462 Free PMC article.
Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.
Uchimoto T, Nakamura K, Komura K, Fukuokaya W, Yano Y, Nishimura K, Kinoshita S, Nishio K, Fukushima T, Nakamori K, Matsunaga T, Tsutsumi T, Tsujino T, Taniguchi K, Tanaka T, Uehara H, Takahara K, Inamoto T, Kimura T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: uehara h. Urol Oncol. 2022 Jul;40(7):344.e11-344.e17. doi: 10.1016/j.urolonc.2022.02.012. Epub 2022 Mar 26. Urol Oncol. 2022. PMID: 35346572
The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in Japan.
Komura K, Hashimoto T, Tsujino T, Muraoka R, Tsutsumi T, Satake N, Matsunaga T, Yoshikawa Y, Takai T, Minami K, Taniguchi K, Uehara H, Tanaka T, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Ohno Y, Azuma H. Komura K, et al. Among authors: uehara h. Ann Surg Oncol. 2019 Sep;26(9):2994-3004. doi: 10.1245/s10434-019-07530-5. Epub 2019 Jun 25. Ann Surg Oncol. 2019. PMID: 31240592
Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort.
Komura K, Fujiwara Y, Uchimoto T, Saito K, Tanda N, Matsunaga T, Ichihashi A, Tsutsumi T, Tsujino T, Yoshikawa Y, Nishimoto Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Azuma H. Komura K, et al. Among authors: uehara h. J Clin Med. 2019 Aug 19;8(8):1251. doi: 10.3390/jcm8081251. J Clin Med. 2019. PMID: 31430900 Free PMC article.
Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer.
Uchimoto T, Komura K, Fujiwara Y, Saito K, Tanda N, Matsunaga T, Ichihashi A, Tsutsumi T, Tsujino T, Yoshikawa Y, Nishimoto Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Azuma H. Uchimoto T, et al. Among authors: uehara h. Med Oncol. 2019 Nov 21;37(1):9. doi: 10.1007/s12032-019-1332-7. Med Oncol. 2019. PMID: 31754918
Adjuvant chemotherapy improves overall survival in patients with localized upper tract urothelial carcinoma harboring pathologic vascular invasion: a propensity score-matched analysis of multi-institutional cohort.
Matsunaga T, Komura K, Hashimoto T, Muraoka R, Satake N, Tsutsumi T, Tsujino T, Yoshikawa Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Ohno Y, Azuma H. Matsunaga T, et al. Among authors: uehara h. World J Urol. 2020 Dec;38(12):3183-3190. doi: 10.1007/s00345-020-03118-x. Epub 2020 Feb 17. World J Urol. 2020. PMID: 32065276
Risk stratification for the prediction of overall survival could assist treatment decision-making at diagnosis of castration-resistant prostate cancer: a multicentre collaborative study in Japan.
Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Fujiwara Y, Matsunaga T, Tsutsumi T, Tsujino T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Ibuki N, Hirano H, Nomi H, Takahara K, Inamoto T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: uehara h. BJU Int. 2021 Feb;127(2):212-221. doi: 10.1111/bju.15187. Epub 2020 Aug 10. BJU Int. 2021. PMID: 32701219
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer.
Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Nishimura K, Nakamori K, Fujiwara Y, Matsunaga T, Tsutsumi T, Tsujino T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Ibuki N, Hirano H, Nomi H, Takahara K, Inamoto T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: uehara h. Cancers (Basel). 2021 Jan 30;13(3):526. doi: 10.3390/cancers13030526. Cancers (Basel). 2021. PMID: 33573172 Free PMC article.
Distinct effect of body mass index by sex as a prognostic factor in localized renal cell carcinoma treated with nephrectomy ~ data from a multi-institutional study in Japan ~.
Tsutsumi T, Komura K, Hashimoto T, Muraoka R, Satake N, Matsunaga T, Tsujino T, Yoshikawa Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Ohno Y, Azuma H. Tsutsumi T, et al. Among authors: uehara h. BMC Cancer. 2021 Feb 27;21(1):201. doi: 10.1186/s12885-021-07883-9. BMC Cancer. 2021. PMID: 33639880 Free PMC article.
Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in Japan.
Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Yano Y, Nishimura K, Nakamori K, Fujiwara Y, Matsunaga T, Tsutsumi T, Tsujino T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Takahara K, Inamoto T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: uehara h. Cancers (Basel). 2021 Jul 15;13(14):3554. doi: 10.3390/cancers13143554. Cancers (Basel). 2021. PMID: 34298768 Free PMC article.
907 results